These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AE BIOFUELS, INC. |
| (Exact name of registrant as specified in its charter) |
|
Nevada
|
26-1407544
|
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(I.R.S.
Employer
Identification
Number)
|
|
Large
accelerated filer
|
o
|
Accelerated
filer
o
|
|
Non-accelerated
filer
(Do
not check if a smaller reporting company)
|
o
|
Smaller
reporting company
þ
|
|
Page
|
||||
|
PART
I
|
||||
|
Special
Note Regarding Forward-Looking Statements
|
1
|
|||
|
Item
1. Business
|
1
|
|||
|
Item
1A. Risk Factors
|
12
|
|||
|
Item
2. Properties
|
23
|
|||
|
Item
3. Legal Proceedings
|
23
|
|||
|
PART
II
|
||||
|
Item
5. Market for Registrant's Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities
|
24
|
|||
|
Item
7. Management’s Discussion and Analysis of Financial Condition and Results
of Operations
|
25
|
|||
|
Item
8. Financial Statements and Supplementary Data
|
35
|
|||
|
Item
9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
|
35
|
|||
|
Item
9A(T). Controls and Procedures
|
35
|
|||
|
Item
9B. Other Information
|
37
|
|||
|
PART
III
|
||||
|
Item
10. Directors, Executive Officers and Corporate Governance
|
38
|
|||
|
Item
11. Executive Compensation
|
43
|
|||
|
Item
12. Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters
|
47
|
|||
|
Item
13. Certain Relationships and Related Transactions, and Director
Independence
|
48
|
|||
|
Item
14. Principal Accounting Fees and Services
|
49
|
|||
|
PART
IV
|
||||
|
Item
15. Exhibits and Financial Statement Schedules
|
50
|
|||
|
Index
to Financial Statements
|
52
|
|||
|
SIGNATURES
|
80
|
|||
|
SPECIAL
NOTE REGARDING FORWARD—LOOKING
STATEMENTS
|
|
|
●
|
The
“India” operating segment encompasses our 50 MGY nameplate capacity
biodiesel manufacturing plant in Kakinada, the administrative offices in
Hyderabad, and holding companies in Nevada and Mauritius. We currently
market and sell our biodiesel to customers in India and to Europe. We
employ our own sales force to sell biodiesel directly to end users and
through independent brokers. For the year ended December 31, 2009 and
2008, revenues from our Indian operations were 100% of total net revenues.
Indian revenues consist of domestic sales within India of biodiesel and
glycerin (a byproduct of biodiesel production) to industrial users,
brokers and local retailers. Export revenues consist of sales of biodiesel
to fuel blenders in Europe. The majority of our consolidated assets as of
December 31, 2009 were attributable to our Indian
operations.
|
|
|
●
|
The
“North America” operating segment encompasses the commercialization of our
proprietary, patent-pending enzyme technology at our integrated cellulose
and starch ethanol demonstration facility in Butte, Montana, land held for
next-generation ethanol plant development in Sutton, Nebraska and our
operations at the ethanol plant in Keyes,
California.
|
|
|
●
|
The
“Other” segment encompasses our costs associated with new market
development, company-wide fund raising, executive compensation and other
corporate expenses.
|
|
|
●
|
Establishes
a National Biofuel Coordination Committee, headed by the Prime Minister of
India and a Biofuel Steering Committee headed by a Cabinet
Secretary;
|
|
|
●
|
Establishes
a biofuel blending target of 20% by 2017, including ethanol and
biodiesel;
|
|
|
●
|
Encourages
biodiesel production from non-edible
sources;
|
|
|
●
|
Recommends
establishing a minimum purchase price for biodiesel linked to the
prevailing retail diesel
price;
|
|
|
●
|
Recommends
that biofuels be brought under the ambit of “Declared Goods” to ensure
unrestricted movement within and outside India;
and
|
|
|
●
|
Recommends
that no taxes and duties should be levied on
biodiesel.
|
|
|
●
|
is
more environmentally friendly than petroleum-based diesel fuel, as
biodiesel has been shown to reduce greenhouse gas, carbon monoxide,
particulate matter and hydrocarbon
emissions;·
|
|
|
●
|
reduces
dependence on imported oil and extends diesel fuel supplies. The U.S.,
Europe and India are currently net importers of crude oil and other fuel
supplies;
|
|
|
●
|
has
excellent engine lubrication characteristics, even when blended with
diesel fuel at low blend rates such as 1% or
2%;
|
|
|
●
|
can
be used in existing diesel engines generally with no or minor engine
modifications;
|
|
|
●
|
is
compatible with the existing diesel fuel distribution infrastructure;
and
|
|
|
●
|
can
be produced from a wide variety of renewable feedstocks including
vegetable oils, such as soybean and palm, or animal
fats.
|
|
|
●
|
Expand market demand for
biodiesel and its byproducts.
We plan to create additional demand
for biodiesel by continuing to produce and market high quality biodiesel
and expand the awareness and acceptance of our product. We intend to
expand our sales channels into neighboring states and large population
centers within India. We also expect to increase sales by selling our
biodiesel into the international market during the summer months when
diesel and biodiesel use in Europe and the United States increases with
the onset of warmer weather.
|
|
|
●
|
Diversify our
feedstocks.
We designed our Kakinada plant with the capability of
producing biodiesel from multiple-feedstocks. In 2008 we produced
biodiesel from refined palm oil and in 2009 we began to produce biodiesel
from palm stearin. Being able to reliably produce, on a continuous-flow
basis, biodiesel from multiple feedstocks that meets our customers’
specifications will mitigate the effect of commodity price
volatility.
|
|
|
●
|
Pursue strategic investment
opportunities.
We believe that there will be opportunities to
expand our business as the biodiesel industry in India continues to grow,
either by acquisitions of other plants or additional capital investment.
We will continue to evaluate opportunities to acquire or invest in
additional biodiesel production and distribution facilities or biodiesel
or other renewable energy production and design technologies in India and
internationally.
|
|
●
|
price;
and
|
|
●
|
quality,
based on the reliability and consistency of our production
processes.
|
|
|
●
|
differences
or unexpected changes in regulatory
requirements;
|
|
|
●
|
political
and economic instability;
|
|
|
●
|
terrorism
and civil unrest;
|
|
|
●
|
work
stoppages or strikes;
|
|
|
●
|
interruptions
in transportation;
|
|
|
●
|
restrictions
on the export or import of
technology;
|
|
|
●
|
difficulties
in staffing and managing international
operations;
|
|
|
●
|
variations
in tariffs, quotas, taxes and other market
barriers;
|
|
|
●
|
longer
payment cycles;
|
|
|
●
|
changes
in economic conditions in the international markets in which our products
are sold; and
|
|
|
●
|
greater
fluctuations in sales to customers in developing
countries.
|
|
|
·
|
limiting
our ability to borrow additional amounts for operating capital or other
purposes and causing us to be able to borrow additional funds only on
unfavorable terms;
|
|
|
·
|
reducing
funds available for operations and distributions because a substantial
portion of our cash flow will be used to pay interest and principal on
debt;
|
|
|
·
|
making
us vulnerable to increases in prevailing interest
rates;
|
|
|
·
|
placing
us at a competitive disadvantage because we may be substantially more
leveraged than some of our
competitors;
|
|
|
·
|
subjecting
all or substantially all of our assets to liens, which means that there
may be no assets left for our shareholders in the event of a liquidation;
and
|
|
|
·
|
limiting
our ability to adjust to changing market conditions, which could increase
our vulnerability to a downturn in our business as a result of general
economic conditions.
|
|
Quarter
Ending
|
High
Bid
|
Low
Bid
|
||||||
|
March
31, 2008
|
$ | 12.00 | $ | 6.00 | ||||
|
June
30, 2008
|
$ | 9.85 | $ | 1.80 | ||||
|
September
30, 2008
|
$ | 9.00 | $ | 3.00 | ||||
|
December
31, 2008
|
$ | 6.50 | $ | 0.38 | ||||
|
March
31, 2009
|
$ | 0.50 | $ | 0.04 | ||||
|
June
30, 2009
|
$ | 0.40 | $ | 0.12 | ||||
|
September
30, 2009
|
$ | 0.30 | $ | 0.10 | ||||
|
December
31, 2009
|
$ | 0.34 | $ | 0.11 | ||||
|
Plan
category
|
Number
of
securities
to
be issued
upon
exercise
of
outstanding
options,
warrants
and
rights
(a)
|
Weighted
average
exercise
price
of
outstanding
options,
warrants
and
rights
(b)
|
Number
of
securities
remaining
available
for
future
issuance
under
equity
compensation
plans (excluding
securities
reflected
in
column
(a))
(c)
|
|||||||||
|
Equity
compensation plans approved by security holders
|
4,697,000
|
$
|
1.37
|
185,410
|
||||||||
|
Equity
compensation plans not approved by security holders
|
0
|
$
|
0
|
0
|
||||||||
|
Total
|
4,697,000
|
$
|
1.37
|
185,410
|
||||||||
|
|
●
|
Overview. Discussion of our
business and overall analysis of financial and other highlights affecting
the Company to provide context for the remainder of
MD&A.
|
|
|
●
|
Results of Operations. An
analysis of our financial results comparing 2009 to
2008.
|
|
|
●
|
Liquidity and Capital
Resources
.
An
analysis of changes in our balance sheets and cash flows, and discussion
of our financial condition.
|
|
|
●
|
Critical Accounting Estimates.
Accounting estimates that we believe are important to understanding the
assumptions and judgments incorporated in our reported financial results
and forecasts.
|
|
|
For
the Year Ended December 31,
|
||||
|
2009
%
|
2008
%
|
||||
|
Salaries,
wages and compensation
|
39
|
|
45
|
||
|
Supplies
and services
|
2
|
|
6
|
||
|
Repair
and maintenance
|
1
|
|
—
|
||
|
Taxes,
insurance, rent and utilities
|
13
|
|
8
|
||
|
Professional
services
|
32
|
|
31
|
||
|
Depreciation
and amortization
|
8
|
|
5
|
||
|
Travel
and entertainment
|
2
|
|
5
|
||
|
Miscellaneous
expense
|
3
|
|
--
|
||
|
Total
|
100
|
|
100
|
||
|
|
·
|
Interest
expense is the result of debt facilities acquired by both the Company and
its India subsidiary. These debt facilities included warrant coverage and
discount fees which are amortized as part of interest expense. We incurred
interest expense of $2,675,403 which was higher than the $614,426 incurred
in the prior year due to the fact that our Third Eye Capital debt and
State Bank of India facilities were outstanding during only a portion of
2008 and were outstanding for the entire fiscal 2009 year. Additionally
our related party loan balance was higher during 2009 as compared to
2008.
|
|
|
·
|
Interest
income is earned on excess cash. Due to the decrease in our cash balances
over the year, as compared to fiscal 2008, our interest income decreased
from $50,691 in fiscal 2008 to $23,327 in fiscal
2009.
|
|
|
·
|
Pursuant
to the terms of its Amended and Restated Registration Rights Agreement,
beginning in January 2008 the Company was obligated to file a registration
statement to register shares of common stock issued or issuable upon
conversion of the Company's Series A and B preferred stock or pay in cash
or shares of stock to these investors an amount equal to 0.5% per month of
their investment amount. The liquidated damages ceased accruing in
December 2008 when the Series B preferred shares became available for
trading in compliance with Rule 144. The Company elected to pay these
liquidated damages through the issuance of 406,656 shares of common stock
to the holders of shares of our Series B preferred stock. The liquidated
damages penalty resulted in an expense of $1,807,746, classified in other
income/expense for the year ended December 31, 2008. The Company issued
the 406,656 shares of its common stock to eligible stockholders on or
about February 12, 2009.
|
|
|
·
|
On
January 23, 2008, we agreed to end the joint venture with Acalmar Oils and
Fats, Ltd. (“Acalmar”) including termination of Acalmar’s right to own or
receive any ownership interest in the joint venture. The total
cancellation price of $900,000 is reflected in our Statement of Operations
as a shareholder agreement cancellation
payment.
|
|
|
·
|
Interest
expense is the result of debt facilities acquired by both the Company and
its India subsidiary. These debt facilities included warrant coverage and
discount fees which are amortized as part of interest expense. We incurred
interest expense of $614,426 and capitalized interest of $929,058 into the
cost of our biodiesel plant in
India.
|
|
|
·
|
Other
income, net of expenses includes $104,810 of income resulting from a
purchase and re-sale of glycerin. Additionally we earned other income from
renting portions our land holdings in Sutton and Danville to local
farmers.
|
|
Payments
Due by Period
|
||||||||||||||||||||||
|
Total
|
Less
Than
1 Year
|
1
- 3
Years
|
3
- 5
Years
|
More
Than
5
Years
|
||||||||||||||||||
|
(In
thousands)
|
||||||||||||||||||||||
|
Debt(a)
|
$
|
15,051,493
|
$
|
10,801,462
|
$
|
4,250,031
|
$
|
--
|
$
|
—
|
||||||||||||
|
Operating
lease obligations(b)
|
632,471
|
263,846
|
368,625
|
—
|
—
|
|||||||||||||||||
|
Construction
purchase obligations(c)
|
—
|
—
|
—
|
—
|
—
|
|||||||||||||||||
|
Total
contractual cash obligations
|
$
|
15,683,964
|
$
|
11,065,308
|
$
|
4,618,656
|
$
|
—
|
$
|
—
|
||||||||||||
|
(a)
|
See
Note 7 – Debt of the Notes to Consolidated Financial Statements. The
amounts included in the table above represent principal maturities
only.
|
|
(b)
|
See
Note 8 – Operating Leases of the Notes to Consolidated Financial
Statements.
|
|
(c)
|
Consists
of firm purchase commitments under construction contracts and commitments
under purchase orders and other short term contracts related to the
construction of the glycerin refinery and pre-treatment plant. See Note 13
— Commitments of the Notes to Consolidated Financial
Statements.
|
|
|
|
December
31,
2009
|
December
31,
2008
|
|
||||
|
Cash
and cash equivalents and time deposits
|
|
$
|
52,178
|
|
$
|
377,905
|
|
|
|
Short
and long term debt
|
|
$
|
15,051,493
|
|
$
|
10,539,766
|
|
|
|
|
·
|
Valuation and amortization
method
— We estimate the fair value of stock options granted using
the Black-Scholes-Merton option-pricing formula and a single option award
approach. This fair value is then amortized on a straight-line basis over
the requisite service periods of the awards, which is generally the
vesting period.
|
|
|
·
|
Expected Term
— The
expected term represents the weighted-average period that our stock-based
awards are expected to be outstanding. We applied the “Simplified Method”
as defined in the Securities and Exchange Commission’s Staff Accounting
Bulletin No. 107.
|
|
|
·
|
Expected Volatility
—
The Company’s expected volatilities are based on the historical volatility
of comparable public companies’ stock for a period consistent with our
expected term.
|
|
|
·
|
Expected Dividend
— The
Black-Scholes-Merton valuation model calls for a single expected dividend
yield as an input. The Company currently pays no dividends and does not
expect to pay dividends in the foreseeable
future.
|
|
|
·
|
Risk-Free Interest Rate
— The Company bases the risk-free interest rate on the implied yield
currently available on United States Treasury zero-coupon issues with an
equivalent remaining term.
|
|
|
·
|
the
prices for our convertible preferred stock sold to outside investors in
arm’s-length transactions;
|
|
|
·
|
the
rights, preferences and privileges of that convertible preferred stock
relative to those of our common
stock;
|
|
|
·
|
our
operating and financial
performance;
|
|
|
·
|
the
hiring of key personnel;
|
|
|
·
|
the
introduction of new products;
|
|
|
·
|
our
stage of development and revenue
growth;
|
|
|
·
|
the
fact that the option grants involved illiquid securities in a private
company;
|
|
|
·
|
the
risks inherent in the development and expansion of our operations;
and
|
|
|
·
|
the
likelihood of achieving a liquidity event, such as an initial public
offering or a sale of us, for the shares of common stock underlying the
options given prevailing market
conditions.
|
|
Name
|
Age
|
Position
|
Director
Since
|
|||
|
Eric
A. McAfee
|
47
|
Chief
Executive Officer and Chairman of the Board
|
2006
|
|||
|
John
R. Block
|
75
|
Director
|
2008
|
|||
|
Michael
Peterson
|
48
|
Director
|
2006
|
|||
|
Harold
Sorgenti
|
75
|
Director
|
2007
|
|
Name
|
Age
|
Position
|
||
|
Andrew
B. Foster
|
44
|
Executive
Vice President and Chief Operating Officer
|
||
|
Sanjeev
Gupta
|
50
|
Managing
Director, Chairman and President (Universal Biofuels Private,
Ltd.)
|
||
|
Scott
A. Janssen
|
40
|
Executive
Vice President and Chief Financial
Officer
|
|
Name
of Director
|
Audit
|
Governance,
Compensation and
Nominating
|
||
|
Michael
Peterson
|
C
|
M
|
||
|
Harold
Sorgenti
|
M
|
C
|
||
|
M
= Member
|
||||
|
C
= Chair
|
|
Name
and Principal Position
|
Year
|
Salary
($)
|
Bonus
($)
|
Option
Awards(1) ($)
|
Total
Compensation
($)
|
|||||||||||||
|
Eric
A. McAfee, Chief Executive Officer
|
2009
|
120,000 | –– | –– | 120,000 | |||||||||||||
|
2008
|
120,000 | –– | –– | 120,000 | ||||||||||||||
|
2007
|
120,000 | –– | –– | 120,000 | ||||||||||||||
|
William
J. Maender, Former Chief Financial Officer and
Secretary(2)
|
2009
|
17,033 | –– | –– | 17,033 | |||||||||||||
|
2008
|
180,000 | –– | –– | 194,332 | ||||||||||||||
|
2007
|
180,000 | –– | 43,002 | 181,393 | ||||||||||||||
|
Andrew
B. Foster, Executive Vice President
|
2009
|
180,000 | 40,123 | 259,915 | ||||||||||||||
|
2008
|
180,000 | 535,054 | 451,475 | |||||||||||||||
|
2007
|
180,000 | 50,000 | 569,409 | 550,989 | ||||||||||||||
|
Sanjeev
Gupta, Executive Vice President
|
2009
|
180,000 | –– | 41,759 | 263,245 | |||||||||||||
|
2008
|
180,000 | –– | 71,340 | 202,305 | ||||||||||||||
|
2007
|
58,038 | –– | 28,668 | 67,594 | ||||||||||||||
|
Scott
A. Janssen, Executive Vice President and Chief Financial
Officer(3)
|
2009
|
180,000 | –– | 33,436 | 246,596 | |||||||||||||
|
2008
|
141,197 | –– | 356,702 | 236,813 | ||||||||||||||
|
2007
|
–– | –– | –– | –– | ||||||||||||||
|
|
(1)
|
These
amounts reflect the value determined by the Company for accounting
purposes for these awards with respect to the current fiscal year and do
not reflect whether the recipient has actually realized a financial
benefit from the awards (such as by exercising stock options). This column
represents the aggregate grant date fair value of stock options granted
during fiscal year 2009 to each of the named executive officers, in
accordance with ASC Topic 718. Pursuant to SEC rules, the amounts shown
exclude the impact of estimated forfeitures related to service-based
vesting conditions. Stock option awards representing 90,000 shares were
forfeited by Mr. Maender who resigned effective January 12, 2009. For
additional information, see Note 11 of our financial statements in the
Form 10-K for the year ended December 31, 2009, as filed with the SEC. For
information on the valuation assumptions for grants made prior to fiscal
year 2009, see the notes in our financial statements in the Form 10-K for
the respective year.
|
|
|
(2)
|
Mr.
Maender resigned effective January 12, 2009. His resignation
resulted in the forfeiture of 90,000 shares subject to stock
options.
|
|
|
(3)
|
Mr.
Janssen was appointed Executive Vice President and Chief Financial Officer
effective January 12, 2009. Mr. Janssen resigned effective March 12, 2010.
His resignation resulted in the forfeiture of 175,000 shares subject to
stock options.
|
|
Option
Awards
|
Stock
Awards
|
||||||||||||||||
|
Name
|
Award
Date
|
No.
of
Securities
underlying
unexercised
options
(#) exercisable
|
No.
of
securities
underlying unexercised
options
(#) unexercisable
|
Equity
incentive
plan
awards:
#
of securities underlying unexercised
unearned
options
(#)
|
Option
exercise
price
($)
|
Option
expiration date
|
Number
of shares or
units
of
stock
that
have
not
vested
(#)
|
Market
value
of
shares
or
units of stock that
have
not vested ($)(1)
|
|||||||||
|
Andrew
B. Foster
|
5/21/09
|
280,000 | (4) | 0.16 |
5/20/14
|
||||||||||||
|
7/17/07
|
275,000 | (2) | 3.00 |
7/16/17
|
|||||||||||||
|
11/26/07
|
67,500 | (3) | 3.00 |
11/26/12
|
|||||||||||||
|
Sanjeev
Gupta
|
5/21/09
|
291,667 | (4) | 0.16 |
5/20/14
|
||||||||||||
|
11/26/07
|
45,000 | (2) | 3.00 |
11/26/12
|
|||||||||||||
|
6/17/08
|
20,000 | (2) | 3.70 |
6/16/13
|
|||||||||||||
|
Scott
Janssen
|
5/21/09
|
233,333 | (4) | 0.16 |
5/20/14
|
||||||||||||
|
6/17/08
|
150,000 | (5) | 3.70 |
6/16/13
|
|||||||||||||
|
|
(1)
|
The
market value of the unvested shares was determined by multiplying the
closing market price of AE Biofuel’s stock at December 31, 2008, the end
of its last completed fiscal year ($0.19), by the number of shares of
stock.
|
|
|
(2)
|
Fifty
percent (50%) of the shares subject to the option were exercisable on the
date of grant and twenty-five percent (25%) of the shares subject to the
option vest on the anniversary of the date of
grant.
|
|
|
(3)
|
One-twelfth
(1/12) of the shares subject to the option vest every three months from
the date of grant.
|
|
|
(4)
|
Fifty
percent (50%) of the shares subject to the option were exercisable on the
date of grant and one-twelfth (1/12) of the shares subject to the option
vest every three months from the date of
grant.
|
|
|
(5)
|
One-eighth
(1/8) of the shares subject to the option vest every three months from the
date of grant.
|
|
Name
|
Fees
Earned
or
Paid in
Cash
($)*
|
Option
Awards(1)
($)
|
Total
($)
|
|||||||||
|
Michael
Peterson (2)
|
112,250 | 16,718 | 145,548 | |||||||||
|
Harold
Sorgenti (3)
|
83,750 | 16,718 | 117,048 | |||||||||
|
John
R. Block(4)
|
78,000 | 16,718 | 111,298 | |||||||||
|
|
(1)
|
The
amounts in this column represent the aggregate grant date fair value under
ASC Topic 718. The assumptions made when calculating the amounts in this
table are found in Note 11 to AE Biofuels’ consolidated financial
statements included in the Company’s Annual Report on Form 10-K for the
fiscal year ended December 31,
2009.
|
|
|
(2)
|
On
May 21, 2009, the Company granted Mr. Peterson an option to purchase
200,000 shares of the Company’s common stock at an exercise price of $0.16
per share in consideration for his services on the Company’s Board of
Directors. Fifty percent (50%) of the shares subject to the option were
exercisable on the date of grant and one-twelfth (1/12) of the shares
subject to the option vest every three months from the date of grant
subject to Mr. Peterson’s continuing service on the Company’s Board of
Directors. At December 31, 2009, Mr. Peterson held 300,000 stock options
awards.
|
|
|
(3)
|
On
May 21, 2009, the Company granted Mr. Sorgenti an option to purchase
200,000 shares of the Company’s common stock at an exercise price of $0.16
per share in consideration for his services on the Company’s Board of
Directors. Fifty percent (50%) of the shares subject to the option were
exercisable on the date of grant and one-twelfth (1/12) of the shares
subject to the option vest every three months from the date of grant
subject to Mr. Sorgenti’s continuing service on the Company’s Board of
Directors. At December 31, 2009, Mr. Sorgenti held 300,000 stock option
awards.
|
|
|
(4)
|
On
May 21, 2009, the Company granted Mr. Block an option to purchase 200,000
shares of the Company’s common stock at an exercise price of $0.16 per
share in consideration for his services on the Company’s Board of
Directors. Fifty percent (50%) of the shares subject to the option were
exercisable on the date of grant and one-twelfth (1/12) of the shares
subject to the option vest every three months from the date of grant
subject to Mr. Block’s continuing service on the Company’s Board of
Directors. At December 31, 2009, Mr. Block held 300,000 stock option
awards.
|
|
Common
Stock
|
Series
B Preferred Stock
|
|||||||||||||||
|
Name
and Address
|
Amount
and
Nature
of Beneficial
Ownership
|
Percentage
of
Class
|
Amount
and
Nature
of
Beneficial
Ownership
|
Percentage
of
Class
|
||||||||||||
|
Officers
& Directors
|
||||||||||||||||
|
Eric
A. McAfee (1)
|
13,000,000 | 15.08 | % | |||||||||||||
|
John
R. Block (2)
|
200,000 | * | ||||||||||||||
|
Michael
L. Peterson (3)
|
836,233 | * | ||||||||||||||
|
Harold
Sorgenti (4)
|
225,000 | * | ||||||||||||||
|
Andrew
Foster (5)
|
875,000 | * | ||||||||||||||
|
Sanjeev
Gupta (6)
|
585,833 | * | ||||||||||||||
|
Scott
A. Janssen (7)
|
425,000 | * | ||||||||||||||
|
All
officers and directors as a group (7 Persons)
|
16,147,066 | 18.28 | % | |||||||||||||
|
5%
or more Holders
|
||||||||||||||||
|
Laird
Cagan (8)
|
14,165,069 | 16.44 | % | |||||||||||||
|
20400
Stevens Creek Blvd., Suite 700
|
||||||||||||||||
|
Cupertino,
CA 95014
|
||||||||||||||||
|
Liviakis
Financial Communications, Inc.
|
4,400,000 | 5.11 | % | |||||||||||||
|
655
Old Redwood Hwy, #395
|
||||||||||||||||
|
Mill
Valley, CA 94941
|
||||||||||||||||
|
Surendra
Ajjarapu
|
6,900,000 | 8.01 | % | |||||||||||||
|
8604
Button Bush Court
|
||||||||||||||||
|
Tampa,
FL 33647
|
||||||||||||||||
|
Michael
C Brown Trust dated June 30, 2000
|
599,999 | 18.07 | % | |||||||||||||
|
34
Meadowview Drive
|
||||||||||||||||
|
Northfield,
IL 60093
|
||||||||||||||||
|
Mahesh
Pawani
|
400,000 | 12.05 | % | |||||||||||||
|
Villa
No. 6, Street 29, Community 317, Al Mankhool,
|
||||||||||||||||
|
Dubai,
United Arab Emirates
|
||||||||||||||||
|
Frederick
WB Vogel
|
408,332 | 12.30 | % | |||||||||||||
|
1660
N. La Salle Drive, Apt 2411
|
||||||||||||||||
|
Chicago,
IL 60614
|
||||||||||||||||
|
Fred
Mancheski
|
300,000 | 9.03 | % | |||||||||||||
|
1060
Vegas Valley Dr
|
||||||||||||||||
|
Las
Vegas, NV 89109
|
||||||||||||||||
|
David
J. Lies
|
200,000 | 6.02 | % | |||||||||||||
|
1210
Sheridan Road
|
||||||||||||||||
|
Wilmette,
IL 60091
|
||||||||||||||||
|
Crestview
Capital, LLC
|
166,667 | 5.02 | % | |||||||||||||
|
95
Revere Dr., Ste A
|
||||||||||||||||
|
Northbrook,
IL 60062
|
||||||||||||||||
|
———————
|
|
|
*Less
than 1%
|
|
|
(1)
|
Includes
(i) 12,200,000 shares held by McAfee Capital, LLC, a company owned by Mr.
McAfee and his wife; and (ii) 800,000 shares owned by P2 Capital, LLC, a
company owned by Mr. McAfee's wife and
children.
|
|
|
(2)
|
Includes
200,000 shares issuable pursuant to options exercisable within 60 days of
March 3, 2010.
|
|
|
(3)
|
Address:
17 Canary Court, Danville, California 94526. Includes 583,818 shares
held by the Michael L Peterson and Shelly P. Peterson Family Trust dtd
8/16/00, and 225,000 shares issuable to Mr. Peterson pursuant to options
exercisable within 60 days of March 3,
2010.
|
|
|
(4)
|
Includes
225,000 shares issuable pursuant to options exercisable within 60 days of
March 3, 2010.
|
|
|
(5)
|
Includes
(i) 200,000 shares held by the Andrew B. Foster and Catherine H. Foster
Trust; and (ii) 675,000 shares issuable pursuant to options exercisable
within 60 days of March 3, 2010.
|
|
|
(6)
|
Includes
385,832 shares issuable pursuant to options exercisable within 60 days of
March 3, 2010.
|
|
|
(7)
|
Includes
404,166 shares issuable pursuant to options exercisable within 60 days of
March 3, 2010.
|
|
|
(8)
|
Includes
(i) 12,907,000 shares held by Cagan Capital, LLC, a company owned by Mr.
Cagan; (ii) 400,000 shares owned by the KRC Trust and 400,000 owned by the
KQC Trust, trusts for Mr. Cagan's daughters for which Mr. Cagan is trustee
and (iii) 458,069 held by Mr. Cagan
individually.
|
|
2009
|
2008
|
|||||||
|
Audit
Fees
|
$ | 254,587 | $ | 344,380 | ||||
|
Audit-Related
Fees
|
–– | –– | ||||||
|
Total
Audit and Audit-Related Fees
|
254,587 | 344,380 | ||||||
|
Tax
Fees
|
35,308 | 47,085 | ||||||
|
All
Other Fees
|
–– | –– | ||||||
|
Total
for independent public audit firms
|
$ | 289,895 | $ | 391,465 | ||||
|
Consolidated
Financial Statements
|
|
I
ndex To Financial Statements
|
Page
Number
|
|||
|
|
|
|||
|
Report
of Independent Registered Public Accounting Firm
|
52 | |||
|
|
||||
|
Consolidated
Financial Statements
|
||||
|
|
||||
|
Consolidated Balance Sheets
|
53 | |||
|
|
||||
|
Consolidated Statements of Operations and
Comprehensive Loss
|
54 | |||
|
|
||||
|
Consolidated Statements of Cash
Flows
|
55 | |||
|
|
||||
|
Consolidated Statements of Stockholders' (Deficit)
Equity
|
56 | |||
|
|
||||
|
Notes to Consolidated Financial
Statements
|
57 | |||
|
2009
|
2008
|
|||||||
|
Assets
|
||||||||
|
Current
assets:
|
||||||||
|
Cash
and cash equivalents
|
$ | 52,178 | $ | 377,905 | ||||
|
Accounts
receivable
|
32,032 | - | ||||||
|
Inventories
|
593,461 | 1,049,583 | ||||||
|
Prepaid
expenses
|
21,660 | 110,581 | ||||||
|
Other
current assets
|
369,668 | 438,703 | ||||||
|
Total
current assets
|
1,068,999 | 1,976,772 | ||||||
|
Property,
plant and equipment, net
|
18,447,875 | 21,236,604 | ||||||
|
Intangible
assets
|
- | 33,333 | ||||||
|
Other
assets
|
49,344 | 289,990 | ||||||
|
Total
assets
|
$ | 19,566,218 | $ | 23,536,699 | ||||
|
Liabilities
and stockholders' (deficit) equity
|
||||||||
|
Current
liabilities:
|
||||||||
|
Accounts
payable
|
$ | 3,137,480 | $ | 2,829,117 | ||||
|
Short
term borrowings, net of discount
|
6,409,950 | 4,504,062 | ||||||
|
Registration
rights liability
|
- | 1,807,748 | ||||||
|
Mandatorily
redeemable Series B Preferred stock
|
1,750,002 | 1,750,002 | ||||||
|
Other
current liabilities
|
3,316,931 | 1,616,259 | ||||||
|
Current
portion of long term debt
|
4,391,512 | 816,738 | ||||||
|
Total
current liabilities
|
19,005,875 | 13,323,926 | ||||||
|
Long
term debt, net of discount
|
- | 3,174,275 | ||||||
|
Long
term debt (related party)
|
4,250,031 | 2,044,691 | ||||||
|
Commitments
and contingencies (Notes 2,4,7,8,9,14,16 and 18 )
|
||||||||
|
Stockholders'
(deficit) equity:
|
||||||||
|
AE
Biofuels, Inc. stockholders (deficit) equity
|
||||||||
|
Series
B Preferred Stock - $.001 par value - 7,235,565 authorized; 3,320,725 and
3,451,892 shares issued and outstanding, respectively (aggregate
liquidation preference of $9,992,175 and $10,355,676,
respectively)
|
3,321 | 3,452 | ||||||
|
Common
Stock - $.001 par value 400,000,000 authorized; 86,181,532 and 85,643,709
shares issued and outstanding, respectively
|
86,181 | 85,643 | ||||||
|
Additional
paid-in capital
|
36,763,984 | 34,238,925 | ||||||
|
Accumulated
deficit
|
(38,804,417 | ) | (27,831,340 | ) | ||||
|
Accumulated
other comprehensive income
|
(1,376,382 | ) | (1,502,873 | ) | ||||
|
Total
AE Biofuels, Inc. stockholders (deficit) equity
|
(3,327,313 | ) | 4,993,807 | |||||
|
Noncontrolling
interest
|
(362,375 | ) | - | |||||
|
Total
stockholders' (deficit) equity
|
(3,689,688 | ) | 4,993,807 | |||||
|
Total
liabilities and stockholders' (deficit) equity
|
$ | 19,566,218 | $ | 23,536,699 | ||||
|
For
the year ended December 31,
|
||||||||
|
2009
|
2008
|
|||||||
|
Sales
|
$ | 9,175,346 | $ | 815,655 | ||||
|
Cost
of goods sold
|
9,046,663 | 2,214,364 | ||||||
|
Gross
profit
|
128,683 | (1,398,709 | ) | |||||
|
Research
and development
|
538,912 | 1,036,948 | ||||||
|
Selling,
general and administrative expenses
|
6,259,527 | 9,730,022 | ||||||
|
Loss
on forward purchase commitments
|
- | 532,500 | ||||||
|
Impairment
of long lived assets
|
2,086,350 | - | ||||||
|
Operating
loss
|
(8,756,106 | ) | (12,698,179 | ) | ||||
|
Other
income / (expense)
|
||||||||
|
Interest
income
|
23,327 | 50,691 | ||||||
|
Interest
expense
|
(2,675,403 | ) | (614,426 | ) | ||||
|
Other
income, net of expenses
|
72,730 | 148,793 | ||||||
|
Share
agreement cancellation payment
|
- | (900,000 | ) | |||||
|
Registration
rights payment
|
- | (1,807,748 | ) | |||||
|
Loss
before income taxes
|
(11,335,452 | ) | (15,820,869 | ) | ||||
|
Income
taxes
|
- | (15,076 | ) | |||||
|
Net
loss
|
(11,335,452 | ) | (15,835,945 | ) | ||||
|
Less:
Net loss attributable to the noncontrolling interest
|
(362,375 | ) | - | |||||
|
Net
loss attributable to AE Biofuels, Inc.
|
$ | (10,973,077 | ) | $ | (15,835,945 | ) | ||
|
Other
comprehensive loss, net of tax
|
||||||||
|
Foreign
currency translation adjustment
|
126,491 | (3,227,958 | ) | |||||
|
Comprehensive
loss, net of tax
|
(11,208,961 | ) | (19,063,903 | ) | ||||
|
Comprehensive
loss attributable to the noncontrolling interest
|
- | - | ||||||
|
Comprehensive
loss attributable to AE Biofuels, Inc.
|
$ | (10,846,586 | ) | $ | (19,063,903 | ) | ||
|
Loss
per common share attributable to AE Biofuels, Inc.
|
||||||||
|
Basic
and dilutive
|
$ | (0.13 | ) | $ | (0.19 | ) | ||
|
Weighted
average shares outstanding
|
||||||||
|
Basic
and dilutive
|
86,110,932 | 84,641,642 | ||||||
|
For
the year ended December 31,
|
|||||||||
|
2009
|
2008
|
||||||||
|
Operating
activities:
|
|||||||||
|
Net
loss
|
$ | (11,335,452 | ) | $ | (15,835,945 | ) | |||
|
Adjustments
to reconcile net loss to
|
|||||||||
|
net
cash used in operating activities:
|
|||||||||
|
Stock
based compensation
|
717,718 | 1,981,524 | |||||||
|
Expired
land options
|
40,000 | 124,536 | |||||||
|
Amortization
and depreciation
|
800,588 | 425,033 | |||||||
|
Inventory
provision
|
863,065 | 1,365,682 | |||||||
|
Amortization
of debt discount
|
571,572 | 532,500 | |||||||
|
Registration
rights obligation
|
- | 1,807,748 | |||||||
|
Impairment
of long lived assets
|
2,086,350 | - | |||||||
|
Changes
in assets and liabilities:
|
|||||||||
|
Accounts
receivable
|
(31,376 | ) | 8,621,006 | ||||||
|
Inventory
|
(371,638 | ) | (2,537,088 | ) | |||||
|
Prepaid
expenses
|
89,318 | (54,996 | ) | ||||||
|
Other
current assets and other assets
|
849,976 | (652,809 | ) | ||||||
|
Accounts
payable
|
265,459 | (6,480,203 | ) | ||||||
| Accrued interest expense | 1,480,170 | 826,562 | |||||||
|
Other
liabilities
|
1,618,027 | 1,230,257 | |||||||
|
Income
taxes payable
|
- | (34,092 | ) | ||||||
|
Net
cash used in operating activities
|
(2,356,223 | ) | (8,680,285 | ) | |||||
|
Investing
activities:
|
|||||||||
|
Purchase
of property, plant and equipment
|
(49,515 | ) | (5,192,124 | ) | |||||
|
Sales
of time deposits
|
- | 2,373,326 | |||||||
|
Cash
payments to settle forward contracts
|
- | (200,115 | ) | ||||||
|
Cash
restricted by letter of credit
|
- | 500,000 | |||||||
|
Net
cash used in investing activities
|
(49,515 | ) | (2,518,913 | ) | |||||
|
Financing
activities:
|
|||||||||
|
Proceeds
from borrowings under related party credit facility
|
1,985,500 | 4,500,000 | |||||||
|
Payments
of borrowings under related party credit facility
|
(80,000 | ) | - | ||||||
|
Proceeds
under working capital facility
|
3,048,903 | - | |||||||
|
Payments
under working capital facility
|
(2,733,498 | ) | - | ||||||
|
Proceeds
from long term debt
|
8,374,313 | ||||||||
|
Payments
under long term debt facility
|
- | (1,967,693 | ) | ||||||
|
Net
cash provided by financing activities
|
2,220,905 | 10,906,620 | |||||||
|
Effect
of exchange rate changes on cash and cash equivalents
|
(140,894 | ) | (49,919 | ) | |||||
|
Net
cash decrease for period
|
(325,727 | ) | (342,497 | ) | |||||
|
Cash
and cash equivalents at beginning of period
|
377,905 | 720,402 | |||||||
|
Cash
and cash equivalents at end of period
|
$ | 52,178 | $ | 377,905 | |||||
|
Supplemental
disclosures of cash flow information, cash paid:
|
|||||||||
|
Interest
|
395,883 | 534,729 | |||||||
|
Income
taxes, net of refunds
|
- | 51,829 | |||||||
|
Supplemental
disclosures of cash flow information, non-cash
transactions:
|
|||||||||
|
Settlement
of registration rights liability through issuance of stock
|
1,807,748 | - | |||||||
|
Issuance
of warrants in connection with debt facility
|
- | 822,500 | |||||||
|
Borrowings
under related party credit facility
|
3,850,819 | - | |||||||
|
Settlement
of borrowings under related party credit facility
|
(3,850,819 | ) | - | ||||||
| AE Biofuels, Inc. | ||||||||||||||||||||||||||||||||||
|
Paid-in
Capital
|
Accum.
Other
|
|||||||||||||||||||||||||||||||||
|
Series
B Preferred Stock
|
Common
Stock
|
in
excess
|
Accumulated
|
Comprehensive
|
Noncontrolling
|
Total
|
||||||||||||||||||||||||||||
|
Shares
|
Dollars
|
Shares
|
Dollars
|
of
Par
|
Deficit
|
Income
|
Interest
|
Dollars
|
||||||||||||||||||||||||||
|
Balance
at December 31, 2007
|
6,487,491 | $ | 6,487 | 84,557,462 | $ | 84,557 | $ | 33,707,953 | $ | (11,995,395 | ) | $ | 1,725,085 | $ | 23,528,687 | |||||||||||||||||||
|
Stock
based employee compensation
|
1,956,524 | 1,956,524 | ||||||||||||||||||||||||||||||||
|
Series
B to Common conversion
|
(2,461,695 | ) | (2,461 | ) | 2,461,695 | 2,461 | - | |||||||||||||||||||||||||||
|
Warrant
exercise
|
9,430 | 9 | 504,552 | 505 | (514 | ) | - | |||||||||||||||||||||||||||
|
Foreign
currency translation adjustment
|
(3,227,958 | ) | ||||||||||||||||||||||||||||||||
|
Debt
issuance discount
|
822,500 | 822,500 | ||||||||||||||||||||||||||||||||
|
Repurchase
of common stock
|
(1,880,000 | ) | (1,880 | ) | (498,119 | ) | (499,999 | ) | ||||||||||||||||||||||||||
|
Reclass
of Series B to a liability
|
(583,334 | ) | (583 | ) | (1,749,419 | ) | (1,750,002 | ) | ||||||||||||||||||||||||||
|
Net
loss
|
(15,835,945 | ) | (15,835,945 | ) | ||||||||||||||||||||||||||||||
|
Balance
at December 31, 2008
|
3,451,892 | $ | 3,452 | 85,643,709 | $ | 85,643 | $ | 34,238,925 | $ | (27,831,340 | ) | $ | (1,502,873 | ) | $ | 4,993,807 | ||||||||||||||||||
|
Stock
based employee compensation
|
717,718 | 717,718 | ||||||||||||||||||||||||||||||||
|
Series
B to Common conversion
|
(131,167 | ) | (131 | ) | 131,167 | 131 | - | |||||||||||||||||||||||||||
|
Penalty
Share Issuances
|
406,656 | 407 | 1,807,341 | 1,807,748 | ||||||||||||||||||||||||||||||
|
Other
comprehensive income
|
126,491 | 126,491 | ||||||||||||||||||||||||||||||||
|
Net
loss
|
(10,973,077 | ) |
(362,375)
|
(11,335,452 | ) | |||||||||||||||||||||||||||||
|
Balance
at December 31, 2009
|
3,320,725 | $ | 3,321 | 86,181,532 | $ | 86,181 | $ | 36,763,984 | $ | (38,804,417 | ) | $ | (1,376,382 | ) | $ |
(362,375)
|
$ | (3,689,688 | ) | |||||||||||||||
|
|
For
the year ended December 31
|
|||||||
|
|
2009
|
2008
|
||||||
|
Series
B preferred stock
|
3,336,257
|
5,876,301
|
||||||
|
Series
B warrants
|
443,853
|
702,990
|
||||||
|
Common
stock options and warrants
|
4,136,478
|
4,291,853
|
||||||
|
Unvested
restricted stock
|
8,219
|
375,068
|
||||||
|
Total
weighted average number of potentially dilutive shares
excluded
from the diluted net loss per share calculation
|
7,924,807
|
11,246,212
|
||||||
|
|
·
|
Valuation and amortization
method
— We estimate the fair value of stock options granted using
the Black-Scholes-Merton option-pricing formula and a single option award
approach. This fair value is then amortized on a straight-line basis over
the requisite service periods of the awards, which is generally the
vesting period.
|
|
|
·
|
Expected Term
— The
expected term represents the weighted-average period that our stock-based
awards are expected to be outstanding. We applied the “Simplified Method”
as defined in the Securities and Exchange Commission’s Staff Accounting
Bulletin No. 107 and 110.
|
|
|
·
|
Expected Volatility
—
The Company’s expected volatilities are based on the historical volatility
of comparable public companies’ stock for a period consistent with our
expected term.
|
|
|
·
|
Expected Dividend
— The
Black-Scholes-Merton valuation model calls for a single expected dividend
yield as an input. The Company currently pays no dividends and does not
expect to pay dividends in the foreseeable
future.
|
|
|
·
|
Risk-Free Interest Rate
— The Company bases the risk-free interest rate on the implied yield
currently available on United States Treasury zero-coupon issues with an
equivalent remaining term.
|
|
December
31,
|
||||||||
|
2009
|
2008
|
|||||||
|
Raw
materials
|
$
|
389,442
|
$
|
674,069
|
||||
|
Work-in-progress
|
77,123
|
53,251
|
||||||
|
Finished
goods
|
126,896
|
322,263
|
||||||
|
Total
inventory
|
$
|
593,461
|
$
|
1,049,583
|
||||
| December 31, | ||||||||
|
|
2009
|
2008
|
||||||
|
Land
|
$
|
3,358,569
|
$
|
3,656,676
|
||||
|
Buildings
|
11,828,545
|
12,445,883
|
||||||
|
Furniture
and fixtures
|
552,849
|
73,983
|
||||||
|
Machinery
and equipment
|
498,833
|
618,487
|
||||||
|
Construction
in progress
|
3,155,001
|
4,648,149
|
||||||
|
Total
gross property, plant & equipment
|
19,393,797
|
21,443,178
|
||||||
|
Less
accumulated depreciation
|
(945,922
|
)
|
(206,574
|
)
|
||||
|
Total
net property, plant & equipment
|
$
|
18,447,875
|
$
|
21,236,604
|
||||
|
|
December
31,
2009
|
December
31,
2008
|
||||||
|
Current
|
||||||||
|
Short
term deposits
|
$
|
56,221
|
$
|
235,119
|
||||
|
Foreign
input credits
|
256,124
|
112,925
|
||||||
|
Land
options
|
—
|
40,000
|
||||||
|
Other
|
57,323
|
50,659
|
||||||
|
|
$
|
369,668
|
$
|
438,703
|
||||
|
Long Term
|
||||||||
|
Restricted
cash
|
$
|
10,744
|
$
|
267,600
|
||||
|
Deposits
|
38,600
|
22,390
|
||||||
|
|
$
|
49,344
|
$
|
289,990
|
||||
|
|
2009
|
2008
|
||||||
|
Vacation
and wages
|
$ | 655,821 | $ | 75,018 | ||||
|
Duty
and service tax
|
660,571 | - | ||||||
|
Termination
fee
|
600,000 | 600,000 | ||||||
|
Legal
fees
|
425,475 | - | ||||||
|
Repurchase
obligations
|
265,581 | 256,581 | ||||||
|
Other
|
709,483 | 940,599 | ||||||
| $ | 3,316,931 | $ | 1,616,259 | |||||
|
|
December
31,
|
|||||||
|
|
2009
|
2008
|
||||||
|
Revolving
line of credit (related party)
|
$ | 4,250,031 | 2,044,691 | |||||
|
Secured
term loan
|
- | 3,991,013 | ||||||
|
Less:
current portion
|
- | (816,738 | ) | |||||
|
Total
long term debt
|
4,250,031 | 5,218,966 | ||||||
|
Senior
secured note, including accrued interest of $1,017,701 and $0
less
unamortized
discount of $583,985 and $43,200
|
6,083,716 | 4,504,062 | ||||||
|
Unsecured
working capital loan
|
326,234 | - | ||||||
|
Current
portion of secured term loan
|
4,391,512 | 816,738 | ||||||
|
Total
current debt
|
10,801,462 | 5,320,800 | ||||||
|
Total
debt
|
$ | 15,051,493 | $ | 10,539,766 | ||||
|
|
|
Debt
Repayments
|
|
|
|
2010
|
|
$
|
10,801,462
|
|
|
2011
|
|
|
4,250,031
|
|
|
Total
|
|
$
|
15,051,493
|
|
|
|
|
Rental
Payments
|
|
|
|
2010
|
|
$
|
263,846
|
|
|
2011
|
260,206
|
|||
|
2012
|
|
108,419
|
|
|
|
Total
|
|
$
|
632,471
|
|
|
|
Authorized
|
Shares
Issued and
Outstanding
December 31,
|
||||||||||
|
Shares
|
2009
|
2008
|
||||||||||
|
Series
B preferred stock
|
7,235,565
|
3,320,725
|
3,451,892
|
|||||||||
|
Undesignated
|
57,764,435
|
—
|
—
|
|||||||||
|
|
65,000,000
|
3,320,725
|
3,451,892
|
|||||||||
|
|
·
|
Increase
or decrease (other than by redemption or conversion) the total number of
authorized shares of Series B preferred
stock;
|
|
|
·
|
Effect
an exchange, reclassification, or cancellation of all or a part of the
Series B preferred stock, including a reverse stock split, but excluding a
stock split;
|
|
|
·
|
Effect
an exchange, or create a right of exchange, of all or part of the shares
of another class of shares into shares of Series B preferred stock;
or
|
|
|
·
|
Alter
or change the rights, preferences or privileges of the shares of Series B
preferred stock so as to affect adversely the shares of such
series.
|
|
|
Number
of
Warrants
|
Weighted-
Average
Exercise
Price
|
Warrants
Exercisable
|
Remaining
Term
(years)
|
||||||||||||
|
Outstanding,
December 31, 2007
|
1,548,074
|
$
|
3.00
|
1,548,074
|
6.1
|
|||||||||||
|
Granted
|
—
|
—
|
—
|
|||||||||||||
|
Exercised
|
(881,487
|
)
|
3.00
|
(881,487
|
)
|
|||||||||||
|
Outstanding,
December 31, 2008
|
666,587
|
3.00
|
666,587
|
3.45
|
||||||||||||
|
Granted
|
—
|
—
|
—
|
|||||||||||||
|
Exercised
|
—
|
—
|
—
|
|||||||||||||
|
Outstanding,
December 31, 2009
|
666,587
|
3.00
|
666,587
|
2.56
|
||||||||||||
|
Shares
Available
For
Grant
|
Number
of
Shares
|
Weighted-Average
Exercise
Price
|
||||||||||
|
Balance
as of December 31, 2007
|
2,016,000 | 1,984,000 | $ | 3.00 | ||||||||
|
Granted
|
(1,222,000 | ) | 1,222,000 | $ | 3.85 | |||||||
|
Exercised
|
— | — | — | |||||||||
|
Forfeited
|
696,500 | (696,500 | ) | — | ||||||||
|
Balance
as of December 31, 2008
|
1,490,500 | 2,509,500 | $ | 3.24 | ||||||||
|
Authorized
|
882,410 | |||||||||||
|
Granted
|
(2,884,000 | ) | 2,884,000 | 0.16 | ||||||||
|
Exercised
|
— | — | — | |||||||||
|
Forfeited
|
691,625 | (696,500 | ) | 3.14 | ||||||||
|
Balance
as of December 31, 2009
|
180,535 | 4,697,000 | 1.37 | |||||||||
|
|
Number
of
Shares
|
Weighted
Average
Exercise
Price
|
Remaining
Contractual
Term
(In
Years)
|
Aggregate
Intrinsic
Value
1
|
||||||||||||
|
Vested
|
3,190,500
|
$
|
1.60
|
3.64
|
$
|
—
|
||||||||||
|
Unvested
|
1,506,500
|
$
|
0.88
|
2.82
|
—
|
|||||||||||
|
Total
|
4,697,000
|
$
|
1.37
|
3.53
|
$
|
—
|
||||||||||
|
(1)
|
Based
on the $0.19 closing price of AE Biofuels stock on December 31, 2009, as
reported on the Over the Counter Bulletin Board, options had no
aggregate intrinsic
value.
|
|
Fiscal
Year Ended
December
31,
|
||||||||
|
|
2009
|
2008
|
||||||
|
Risk-free
interest rate
|
2.58
|
%
|
3.66
|
%
|
||||
|
Expected
volatility
|
58.88
|
%
|
57.77
|
%
|
||||
|
Expected
life (years)
|
5.00
|
3.96
|
||||||
|
Weighted
average fair value per share of common stock
|
$
|
0.08
|
$
|
1.77
|
||||
|
|
Number
of
Shares
|
Weighted
Average
Grant
Date
Fair
Value
|
||||||
|
Repurchasable
shares as of January 1, 2008
|
1,100,000
|
0.0025
|
||||||
|
Vested
|
(750,000
|
)
|
(0.0025
|
)
|
||||
|
Forfeited
|
(100,000
|
)
|
(0.0025
|
)
|
||||
|
Repurchasable
shares as of December 31, 2008
|
250,000
|
$
|
0.0025
|
|||||
|
Vested
|
(250,000
|
)
|
(0.0025
|
)
|
||||
|
Repurchasable
shares as of December 31, 2009
|
-
|
$
|
-
|
|||||
|
2009
|
2008
|
|||||||||||||||||||||
|
Parent
|
Noncontrolling
Interest
|
Consolidated
|
Parent
|
Noncontrolling
Interest
|
Consolidated
|
|||||||||||||||||
|
December
31,
Accumulated
deficit
|
$
|
(1,426,633
|
)
|
$
|
––
|
$
|
(1,426,633
|
)
|
$
|
(257,760
|
)
|
$ |
––
|
$ |
(257,760
|
)
|
||||||
|
Attributable
net loss
|
(377,166
|
)
|
(362,375
|
)
|
(739,540
|
)
|
(1,168,873
|
)
|
––
|
(1,168,873
|
)
|
|||||||||||
|
December
31,
Accumulated
deficit
|
$
|
(1,803,799
|
)
|
$
|
(362,375
|
)
|
$
|
(2,166,174
|
)
|
$
|
(1,426,633
|
)
|
$ |
––
|
$ |
(1,426,633
|
)
|
|||||
|
|
·
|
The
“India” operating segment encompasses the Company’s 50 MGY nameplate
capacity biodiesel manufacturing plant in Kakinada, the administrative
offices in Hyderabad, India, and the holding companies in Nevada and
Mauritius. The Company’s biodiesel is marketed and sold primarily to
customers in India through brokers and by the Company directly. For the
year ended December 31, 2008, revenues from our Indian operations were
100% of total net revenues. Indian revenues consist of sales of biodiesel
produced by our plant in Kakinada to customers in India. The majority of
the Company’s assets as of December 31, 2008 were attributable to its
Indian operations.
|
|
|
·
|
The
“North America” operating segment includes the Company’s cellulosic
ethanol commercial demonstration facility in Butte, and the land held for
future ethanol plant development in Sutton, NE and in Danville, IL. The
Company is utilizing the Montana demonstration facility to commercialize
its proprietary enzymatic and cellulosic technology. As our technology
gains market acceptance, this business segment will include our domestic
commercial application of the cellulosic technology, our plant
construction projects and any acquisitions of ethanol or ethanol related
technology facilities in North
America.
|
|
|
·
|
The
“Other” segment encompasses the Company’s costs associated with new market
development, company-wide fund raising, formation, executive compensation
and other corporate expenses.
|
|
Statement
of Operations Data
|
Year
Ended
December
31,
|
|||||||
|
|
2009
|
2008
|
||||||
|
Revenues
|
||||||||
|
India
|
$ | 9,175,346 | $ | 815,655 | ||||
|
North
America
|
— | — | ||||||
|
Other
|
— | — | ||||||
|
Total
revenues
|
$ | 9,175,346 | $ | 815,655 | ||||
|
|
||||||||
|
Cost
of goods sold
|
||||||||
|
India
|
$ | 9.046,663 | 2,214,364 | |||||
|
North
America
|
— | — | ||||||
|
Other
|
— | — | ||||||
|
Total
cost of goods sold
|
$ | 9,046,663 | $ | 2,214,364 | ||||
|
|
||||||||
|
Gross
profit
|
||||||||
|
India
|
$ | 128,683 | $ | (1,398,709 | ) | |||
|
North
America
|
— | — | ||||||
|
Other
|
— | — | ||||||
|
Total
gross profit
|
$ | 128,683 | $ | (1,398,709 | ) | |||
|
Balance
Sheet Data
|
Year
Ended
December
31
|
|||||||
|
2009
|
2008
|
|||||||
|
Total
Assets
|
||||||||
|
India
|
$
|
16,224,300
|
$
|
17,764,708
|
||||
|
North
America (United States)
|
3,250,827
|
5,416,705
|
||||||
|
Other
|
91,091
|
355,286
|
||||||
|
Total
Assets
|
$
|
19,566,218
|
$
|
23,536,699
|
||||
| 2009 |
March
31
|
June
30
|
September
30
|
December
31
|
||||||||||||
|
(In
thousands, except per share amounts)
|
||||||||||||||||
|
Net
sales
|
$
|
2,503
|
$
|
994
|
$
|
4,055
|
$
|
1,623
|
||||||||
|
Gross
profit (loss)
|
185
|
(103
|
)
|
370
|
(323
|
)
|
||||||||||
|
Operating
loss
|
(1,709
|
)
|
(1,874
|
)
|
(3,131
|
)
|
(2,042
|
)
|
||||||||
|
Net
income (loss)
|
$
|
(2,528
|
)
|
$
|
(2,460
|
)
|
$
|
(3,785
|
)
|
$
|
(2,562
|
)
|
||||
|
Loss
per common share, basic and fully diluted:
|
$
|
(.03
|
)
|
$
|
(.03
|
)
|
$
|
(.04
|
)
|
$
|
(.03
|
)
|
||||
|
2008
|
||||||||||||||||
|
(In
thousands, except per share amounts)
|
||||||||||||||||
|
Net
sales
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
816
|
||||||||
|
Gross
profit (loss)
|
—
|
—
|
(952
|
)
|
(447
|
)
|
||||||||||
|
Operating
loss
|
(2,086
|
)
|
(4,045
|
)
|
(3,722
|
)
|
(2,845
|
)
|
||||||||
|
Net
income (loss)
|
$
|
(5,233
|
)
|
$
|
(4,273
|
)
|
$
|
(3,651
|
)
|
$
|
(2,679
|
)
|
||||
|
Loss
per common share, basic and fully diluted:
|
$
|
(.06
|
)
|
$
|
(.05
|
)
|
$
|
(.04
|
)
|
$
|
(.04
|
)
|
||||
|
|
Year
Ended December 31,
|
|||||||
|
|
2009
|
2008
|
||||||
|
Current:
|
||||||||
|
Federal
|
$ | — | $ | 4,738 | ||||
|
State
and local
|
— | 4,008 | ||||||
|
Foreign
|
— | 6,330 | ||||||
|
|
15,076 | |||||||
|
|
||||||||
|
Deferred:
|
— | — | ||||||
|
Federal
|
— | — | ||||||
|
State
and local
|
— | — | ||||||
|
Foreign
|
— | — | ||||||
|
Income
tax expense
|
$ | — | $ | 15,076 | ||||
|
Year
Ended December 31,
|
||||||||
|
|
2009
|
2008
|
||||||
|
United
States
|
$
|
(8,776,324
|
)
|
$
|
(12,526,682
|
)
|
||
|
Foreign
|
(2,559,128
|
)
|
(3,294,187
|
)
|
||||
|
Income
before income taxes
|
$
|
(11,335,452
|
)
|
$
|
(15,820,869
|
)
|
||
|
|
Year
Ended December 31,
|
|||||||
|
|
2009
|
2008
|
||||||
|
Income
tax expense at the federal statutory rate
|
$ | (3,670,892 | ) | $ | (5,379,095 | ) | ||
|
Increase
(decrease) resulting from:
|
||||||||
|
State
tax
|
(427,551 | ) | (626,506 | ) | ||||
|
Stock-based
compensation
|
272,446 | 704,066 | ||||||
|
Foreign
loss (income)
|
766,950 | 1,250,473 | ||||||
|
Registration
rights
|
— | 686,221 | ||||||
|
Joint
venture termination fee
|
— | 341,640 | ||||||
|
Other
|
1,138 | 57,146 | ||||||
|
Valuation
allowance
|
3,057,909 | 2,981,131 | ||||||
|
Income
tax expense
|
$ | — | $ | 15,076 | ||||
|
|
||||||||
|
Effective
tax rate
|
(0.00 | )% | (0.10 | )% | ||||
|
|
December
31,
|
|||||||
|
|
2009
|
2008
|
||||||
|
Deferred
tax assets (liabilities):
|
||||||||
|
Organization
and start-up costs
|
$
|
8,106,179
|
$
|
7,351,996
|
||||
|
Stock-based
compensation
|
738,496
|
738,496
|
||||||
|
Property,
plant and equipment
|
(141,710
|
)
|
(933,688
|
)
|
||||
|
Net
operating loss carryforward
|
1,920,009
|
446,101
|
||||||
|
Other,
net
|
57,786
|
112,924
|
||||||
|
Total
deferred tax assets (liabilities)
|
10,680,760
|
7,715,829
|
||||||
|
Less
valuation allowance
|
$
|
(
10,680,760
|
)
|
(7,715,829
|
)
|
|||
|
Deferred
tax assets (liabilities)
|
—
|
—
|
||||||
|
United
States — Federal
|
|
2006
- present
|
|
|
United
States — State
|
|
2005
- present
|
|
|
India
|
|
2006
- present
|
|
|
Mauritius
|
|
2006
- present
|
|
|
|
Fair
Value Measurements
|
||||||||||||
|
Carrying
Amount
at
December 31,
2009
|
Level
1
|
Level
2
|
Level
3
|
||||||||||
|
Assets
|
|||||||||||||
|
Cash
and time deposits
|
$
|
52,178
|
$
|
52,178
|
$
|
––
|
$
|
––
|
|||||
|
Other
assets - restricted cash
|
10,744
|
––
|
10,744
|
––
|
|||||||||
|
Total
|
$
|
62,922
|
$
|
52,178
|
$
|
10,744
|
––
|
||||||
|
|
Fair
Value Measurements
|
||||||||||||
|
Carrying
Amount
at
December 31,
2009
|
Level
1
|
Level
2
|
Level
3
|
||||||||||
|
Assets
|
|||||||||||||
|
Landholdings
in Illinois and Nebraska
|
$
|
2,885,000
|
$
|
––
|
$
|
2,885,000
|
$
|
––
|
|||||
|
SIGNATURES
|
|
|
|
|
|
|
AE
Biofuels, Inc.
|
|
|
|
|
|
|
|
/s/ E
RIC
A. M
C
A
FEE
|
|
|
|
Eric
A. McAfee
|
|
|
|
Chief
Executive Officer
|
|
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
|
|
Title
|
|
Date
|
|
/s/ E
RIC
A. M
C
A
FEE
|
|
Chairman/Chief
Executive Officer
|
|
March
10, 2010
|
|
Eric
A. McAfee
|
|
(Principal
Executive Officer and Director)
|
|
|
|
|
|
|
|
|
|
/s/TODD
WALTZ
|
|
Chief
Financial Officer
|
|
March
15, 2010
|
|
Todd
Waltz
|
|
(Principal
Financial and Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/ M
ICHAEL
P
ETERSON
|
|
Director
|
|
March
12, 2010
|
|
Michael
Peterson
|
|
|
|
|
|
|
|
|
|
|
|
/s/ H
AROLD
S
ORGENTI
|
|
Director
|
|
March
10, 2010
|
|
Harold
Sorgenti
|
|
|
|
|
|
|
|
|
|
|
|
/s/ J
OHN
R. B
LOCK
|
|
Director
|
|
March
10, 2010
|
|
John
R. Block
|
|
|
|
|
|
INDEX
TO EXHIBITS
|
||||||||||||||||||
|
Incorporated
by Reference
|
|
|||||||||||||||||
|
Exhibit
No.
|
Description
|
Form
|
File
No.
|
Exhibit
|
Filing
Date
|
Filed Herewith | ||||||||||||
| 2.1 |
Amended
and Restated Agreement and Plan of Merger By and Among Marwich II, Ltd., a
Colorado corporation, Marwich II Ltd., a Nevada corporation, AE Biofuels,
Inc., a Nevada corporation and wholly-owned subsidiary of Marwich II
Nevada, and American Ethanol, Inc., a Nevada corporation dated as of July
19, 2007
|
8-K | 000-51354 | 2.1 |
July
20, 2007
|
|||||||||||||
| 2.2 |
Agreement
and Plan of Merger by and between Marwich II, Ltd., a Colorado
corporation, and Marwich II, Ltd., a Nevada corporation dated July 19,
2007
|
8-K | 000-51354 | 2.2 |
July
20, 2007
|
|||||||||||||
| 2.3 |
Articles
of Merger between Marwich II, Ltd., a Colorado corporation as the merging
entity and Marwich II, Ltd., a Nevada corporation as the surviving entity
filed with the Nevada Secretary of State on December 6,
2007
|
X | ||||||||||||||||
| 2.4 |
Articles
of Merger between AE Biofuels, Inc., a wholly-owned subsidiary of Marwich
II, Ltd. , as the merging entity and American Ethanol, Inc., a Nevada
corporation as the surviving entity filed with the Nevada Secretary of
State on December 7, 2007
|
X | ||||||||||||||||
| 3.1 |
Articles
of Incorporation of Marwich II, Ltd., a Nevada corporation (renamed AE
Biofuels, Inc.) filed with the Nevada Secretary of State on October 24,
2006
|
10-Q | 000-51354 | 3.1 |
Nov.
14, 2008
|
|||||||||||||
| 3.2 |
Certificate
of Amendment to Articles of Incorporation of Marwich II, Ltd., a Nevada
corporation (renamed AE Biofuels, Inc.) filed with the Nevada Secretary of
State on October 11, 2007
|
10-Q | 000-51354 | 3.1.1 |
Nov.
14, 2008
|
|||||||||||||
| 3.3 |
Certificate
of Designation of Series B Preferred Stock filed with the Nevada Secretary
of State on December 6, 2007
|
8-K | 000-51354 | 3.2 |
Dec.
13, 2007
|
|||||||||||||
| 3.4 |
Certificate
of Amendment to Articles of Incorporation to change the name of the
Company to AE Biofuels, Inc. filed with the Nevada Secretary of State on
December 7, 2007
|
8-K | 000-51354 | 3.3 |
Dec.
13, 2007
|
|||||||||||||
| 3.5 |
Bylaws
|
8-K | 000-51354 | 3.4 |
Dec.
13, 2007
|
|||||||||||||
| 4.1 |
Specimen
Common Stock Certificate
|
8-K | 000-51354 | 4.1 |
Dec.
13, 2007
|
|||||||||||||
| 4.2 |
Specimen
Series B Preferred Stock Certificate
|
8-K | 000-51354 | 4.2 |
Dec.
13, 2007
|
|||||||||||||
| 4.3 |
Form
of Common Stock Warrant
|
8-K | 000-51354 | 4.3 |
Dec.
13, 2007
|
|||||||||||||
| 4.4 |
Form
of Series B Preferred Stock Warrant
|
8-K | 000-51354 | 4.4 |
Dec.
13, 2007
|
|||||||||||||
| 10.1 |
Amended
and Restated 2007 Stock Plan
|
14 | A | 000-51354 |
April
15, 2008
|
|||||||||||||
| 10.2 |
Amended
and Restated 2007 Stock Plan form of Stock Option Award
Agreement
|
14 | A | 000-51354 |
April
15, 2008
|
|||||||||||||
| 10.3 |
Amended
and Restated Registration Rights Agreement, dated February 28,
2007
|
8-K | 000-51354 | 10.3 |
Dec.
13, 2007
|
|||||||||||||
| 10.4 |
Executive
Chairman Agreement, dated January 30, 2006 with Eric A.
McAfee
|
8-K | 000-51354 | 10.4 |
Dec.
13, 2007
|
|||||||||||||
| 10.7 |
Executive
Employment Agreement, dated May 22, 2007 with Andrew
Foster
|
8-K | 000-51354 | 10.7 |
Dec.
13, 2007
|
|||||||||||||
| 10.10 |
Executive
Employment Agreement, dated June 17, 2008 with Scott A.
Janssen
|
10-K | 000-51354 | 10.10 |
May
20, 2009
|
|||||||||||||
| 10.11 |
Executive
Employment Agreement, dated September 1, 2007 with Sanjeev
Gupta
|
10-K | 000-51354 | 10.11 |
May
20, 2009
|
|||||||||||||
| 10.12 |
Agreement
of Loan for Overall Limit
|
10-Q | 000-51354 | 10.12 |
August
14, 2008
|
|||||||||||||
| 10.13 |
Deed
of Guarantee for Overall Limit
|
10-Q | 000-51354 | 10.13 |
August
14, 2008
|
|||||||||||||
| 10.14 |
$5
million Note and Warrant Purchase Agreement dated May 16, 2008 among Third
Eye Capital Corporation, as Agent; the Purchasers; and AE Biofuels, Inc.,
including the form of Note
|
8-K | 000-51354 | 10.1 |
May
21, 2008
|
|||||||||||||
| 10.16 |
Revolving
Line of Credit Agreement between International Biodiesel, Inc., a wholly
owned subsidiary of AE Biofuels, Inc. and Laird Q. Cagan
|
X | ||||||||||||||||
| 10.17 |
Project
Agreement entered into 1st day of December 2009, by and among Cilion,
Inc., a Delaware corporation, AE Biofuels, Inc., a Nevada corporation, AE
Advanced Fuels, Inc., a Delaware corporation and AE Advanced Fuels Keyes,
Inc., a Delaware corporation.
|
8-K | 000-51354 | 10.1 |
Dec.
2, 2009
|
|||||||||||||
| 10.18 |
Lease
Agreement for Keyes, California Ethanol Production Facility entered into
1st day of December, 2009, by and between Cilion, Inc., a Delaware
corporation, AE Advanced Fuels Keyes, Inc., a Delaware corporation and AE
Advanced Fuels, Inc., a Delaware corporation, each of which are
wholly-owned subsidiaries of AE Biofuels, Inc., a Nevada
corporation.
|
8-K | 000-51354 | 10.2 |
Dec.
2, 2009
|
|||||||||||||
| 10.19 |
Amendment
No. 4 and Limited Waiver to Note and Warrant Purchase Agreement dated
December 10, 2009, between AE Biofuels, Inc. and Third Eye Capital
Corporation
|
8-K | 000-51354 | 10.1 |
Dec.
22, 2009
|
|||||||||||||
| 10.20 |
Assignment
of Proceeds Agreement dated as of December 10, 2009, between AE Biofuels,
Inc. and Third Eye Capital Corporation
|
8-K | 000-51354 | 10.2 |
Dec.
22, 2009
|
|||||||||||||
| 10.21 |
Guaranty
Agreement dated as of December 10, 2009, between AE Advanced Fuels Keyes,
Inc. and Third Eye Capital Corporation
|
8-K | 000-51354 | 10.3 |
Dec.
22, 2009
|
|||||||||||||
| 14 |
Code
of Ethics
|
10-K | 000-51354 | 14 |
May
20, 2009
|
|||||||||||||
| 21.1 |
Subsidiaries
of the Registrant
|
000-51354 | X | |||||||||||||||
| 24.1 |
Power
of Attorney (see signature page)
|
000-51354 | X | |||||||||||||||
| 31.1 |
Rule
13a-14(a)/15d-14(a) Certification by the Chief Executive
Officer
|
000-51354 | X | |||||||||||||||
| 31.2 |
Rule
13a-14(a)/15d-14(a) Certification by the Chief Financial Officer
Certification by the Chief Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
000-51354 | X | |||||||||||||||
| 32.1 |
Certification
by the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
000-51354 | X | |||||||||||||||
| 32.2 |
Rule
13a-14(a)/15d-14(a) Certification by the Chief Financial Officer
Certification by the Chief Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
000-51354 | X |
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|